Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Lawmakers push energy drink investigation; Innophos buys Triarco; BASF sweetens Pronova bid; meclizine mix-up spurs iron supplement recall; Abbott Nutrition margin growth on track; Neptune’s struggles continue; Vitamin Shoppe reaches Canada; more news In Brief.

You may also be interested in...



FDA Energy Drink Plans Earn Durbin’s Stamp; Firms Meet With Agency

Senate critics say FDA “is moving forward in a number of areas to protect vulnerable populations against high levels of caffeine in energy drinks.” Monster Energy and Rockstar representatives tell FDA their products are safe. Rep. Markey asks FTC to scrutinize advertising for the products.

In Brief

BASF casts bid for Pronova BioPharma; Bayer will not top Reckitt’s Schiff bid; FDA expands arsenal against tainted supplements; CHPA launches anti-smurfing initiative; Bovine ingredients trip Atrium; more news in brief.

Harvard Drug Continues Expansion With Watson’s Rugby OTC Business

Watson Pharmaceuticals sells OTC business Rugby Laboratories to Harvard Drug Group, which operates Major Pharmaceuticals manufacturing. Watson divests a business that accounted for a small part of the private label OTC market, but keeps its pending ANDAs for guaifenesin expectorants and its smoking-cessation generics.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel